Health Yuan Haibin Pharmaceutical Co., Ltd.

Health Yuan Haibin Pharmaceutical Co., Ltd. was established in 2018 with a registered capital of RMB 500 million. It is located in Pingshan District, Shenzhen, and was jointly invested and established by Health Yuan Pharmaceutical Group Joint-stock Co., Ltd. and Shenzhen Haibin Pharmaceutical Co., Ltd. The company covers an area of approximately 45,000 square meters, with a building area of approximately 117,000 square meters. It is a modern pharmaceutical enterprise integrating research and development and production.
Since its establishment, the company has been repeatedly recognized in scientific and technological innovation, green development, and social responsibility: in 2021, it was rated as a "High-tech Enterprise" and a "Specialized, Refined, Distinctive, and Innovative Small and Medium-sized Enterprise of Shenzhen"; in 2022, it was approved to establish the "Guangdong Provincial Engineering Technology Research Center for Key Technology Research and Innovative Technology Application of Inhalation Preparation Industrialization"; in 2024, it completed the filing of the "Guangdong Provincial Secondary Pathogenic Microorganism Laboratory". In addition, the company has successively won multiple honors such as the "Pingshan District Outstanding Contribution Industrial Enterprise Award", "Shenzhen Sponge City Model Project", "Shenzhen Green Building Design Certification", and "Green Factory".
In terms of management systems, the company has fully passed the certifications of the Quality Management System (ISO9001), Environmental Management System (ISO14001), Occupational Health and Safety Management System (ISO45001), Energy Management System (ISO50001), Compliance Management System (GB/T35770-2022/ISO37301), and Intellectual Property Management System (GB/T29490), building a complete, standardized, and efficient comprehensive operation system. As of now, the company has obtained a total of 61 authorized patents, including 9 invention patents, demonstrating solid research and development strength and technological accumulation.
As an important pharmaceutical research and production base under Health Yuan Group, the company is equipped with multiple preparation production lines, covering various dosage forms such as inhalation solutions, inhalation suspensions, inhalation powders, lyophilized powder injections (microcrystalline), small-volume injections (vials/nanocrystals, prefilled syringes/nanocrystals), as well as tablets, capsules, and dry suspensions (spray drying). The main production lines have all passed China GMP compliance inspections, among which the inhalation solution and inhalation suspension production lines were the first to pass PIC/S GMP certification, possessing a production quality system in line with international standards.
The company's products focus on the respiratory field. The marketed varieties include: Mapatricitabine Capsules (Yilikang), Tobramycin Inhalation Solution (Jianketuo), Budesonide Suspension for Inhalation (Wushu), Salmeterol Fluticasone Inhalation Powder (Jiankechang), Compound Ipratropium Bromide Solution for Inhalation (Shutanlin), Ipratropium Bromide Solution for Inhalation (Liwuan), Terbutaline Sulfate Nebulizer Inhalation Solution (Teruitong), Fluticasone Propionate Nebulizer Inhalation Suspension (Jiankeshun), Formoterol Fumarate Inhalation Solution (Jiankefu), Levalbuterol Hydrochloride Inhalation Solution (Lishutong), etc. The innovative drug pipeline under research covers more than ten varieties such as Mapatricitabine Dry Suspension, small molecule glucocorticoid new drugs, and inhaled PDE4 inhibitors, continuously promoting innovation and development in the field of respiratory therapy.